Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Individualized Targeting and Neuromodulation of Late-Life Depression

NCT04543773 · tracked via the Priya Life Science Mexico tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2026-10-09

Condition(s) studied

Major Depressive Disorder

Investigational drug(s) / intervention(s)

rTMS

rTMS: rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.

Study summary

An open-label, single-arm, clinical research study about how to make transcranial magnetic stimulation (TMS), an FDA-approved treatment, more effective for patients with late-life depression using fMRI.

Eligibility

Sex
ALL
Min age
60 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: 1. Participant must be at least 60 years of age (all genders, races, and ethnicities), and less than or equal to 79 years of age. 2. Participant must have a diagnosis of major depressive disorder without psychosis for the past 6 months, as diagnosed by a board-certified psychiatrist 3. Must show evidence of being in a current major depressive episode, as indicated by score on QIDS-C of 10 or higher. 4. Participant must not have any conditions listed in the exclusion criteria 5. Participant must be fluent in English Exclusion Criteria: 1. Current diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or any other psychotic disorder 2. Substance use disorder, abuse or dependence, with active use within the last 3 months 3. Legal or mental incompetency, or inability to consent to study 4. Unstable medical illness, or hospitalization within 3 weeks of study entry 5. Current diagnosis of a neurological disorder or neurocognitive disorder 6. Prior neurosurgical procedure 7. History of seizure 8. History of ECT treatment within the past three months 9. History of any previous TMS treatment 10. Any contraindication to obtaining magnetic resonance imaging safely 11. Pregnant women 12. Inability to complete the protocol, namely, inability to independently attend all study visits and TMS sessions on time.

Primary outcome measure(s)

  • Anterior Cingulate Cortex (ACC) Connectivity — Week 3 post-treatment assessment
    Change in baseline correlation index of the ACC network on resting state fMRI

Trial sites (1)

FacilityCityRegionStatus
University of New Mexico HSC Albuquerque New Mexico
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04543773 on ClinicalTrials.gov ↗ ← All trials in Mexico